{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:38:40Z","timestamp":1771025920580,"version":"3.50.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40266-020-00822-6","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T08:02:33Z","timestamp":1608710553000},"page":"17-27","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy"],"prefix":"10.1007","volume":"38","author":[{"given":"Joon-Bom","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9091-1216","authenticated-orcid":false,"given":"Eleonora M.","family":"Lad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"issue":"6","key":"822_CR1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/archophthalmol.2010.92","volume":"128","author":"R Klein","year":"2010","unstructured":"Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol Chic Ill 1960. 2010;128(6):750\u20138. https:\/\/doi.org\/10.1001\/archophthalmol.2010.92.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"9827","key":"822_CR2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet LondEngl. 2012;379(9827):1728\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(12)60282-7.","journal-title":"Lancet LondEngl"},{"issue":"7","key":"822_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/aje\/kwf092","volume":"156","author":"R Klein","year":"2002","unstructured":"Klein R, Klein BEK, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am J Epidemiol. 2002;156(7):589\u201398. https:\/\/doi.org\/10.1093\/aje\/kwf092.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"822_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0161-6420(03)00599-2","volume":"110","author":"R Klein","year":"2003","unstructured":"Klein R, Klein BEK, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110(6):1273\u201380. https:\/\/doi.org\/10.1016\/S0161-6420(03)00599-2.","journal-title":"Ophthalmology"},{"issue":"6","key":"822_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/archopht.1995.01100060069034","volume":"113","author":"JA Mares-Perlman","year":"1995","unstructured":"Mares-Perlman JA, Brady WE, Klein R, VandenLangenberg GM, Klein BE, Palta M. Dietary fat and age-related maculopathy. Arch Ophthalmol Chic Ill 1960. 1995;113(6):743\u20138. https:\/\/doi.org\/10.1001\/archopht.1995.01100060069034.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"6","key":"822_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0039-6257(88)90052-5","volume":"32","author":"NM Bressler","year":"1988","unstructured":"Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375\u2013413. https:\/\/doi.org\/10.1016\/0039-6257(88)90052-5.","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"822_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.ophtha.2012.03.016","volume":"119","author":"MG Erke","year":"2012","unstructured":"Erke MG, Bertelsen G, Peto T, Sj\u00f8lie AK, Lindekleiv H, Nj\u00f8lstad I. Prevalence of age-related macular degeneration in elderly Caucasians: the Troms\u00f8 Eye Study. Ophthalmology. 2012;119(9):1737\u201343. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.016.","journal-title":"Ophthalmology"},{"issue":"5","key":"822_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","volume":"121","author":"FG Holz","year":"2014","unstructured":"Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren CM. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2013.11.023.","journal-title":"Ophthalmology"},{"issue":"1","key":"822_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajo.2014.04.016","volume":"158","author":"C-J Chiu","year":"2014","unstructured":"Chiu C-J, Chang M-L, Zhang FF, et al. The relationship of major American dietary patterns to age-related macular degeneration. Am J Ophthalmol. 2014;158(1):118\u201327. https:\/\/doi.org\/10.1016\/j.ajo.2014.04.016 (e1).","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"822_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ophtha.2013.10.017","volume":"121","author":"JJ Wang","year":"2014","unstructured":"Wang JJ, Buitendijk GHS, Rochtchina E, et al. Genetic susceptibility, dietary antioxidants, and long-term incidence of age-related macular degeneration in two populations. Ophthalmology. 2014;121(3):667\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.017.","journal-title":"Ophthalmology"},{"issue":"10","key":"822_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","unstructured":"Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol Chic Ill 1960. 2001;119(10):1417\u201336. https:\/\/doi.org\/10.1001\/archopht.119.10.1417.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"19","key":"822_CR12","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.2013.4997","volume":"309","author":"Age-Related Eye Disease Study 2 Research Group","year":"2013","unstructured":"Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005\u201315. https:\/\/doi.org\/10.1001\/jama.2013.4997.","journal-title":"JAMA"},{"issue":"1","key":"822_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ijc.25008","volume":"127","author":"N Druesne-Pecollo","year":"2010","unstructured":"Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer. 2010;127(1):172\u201384. https:\/\/doi.org\/10.1002\/ijc.25008.","journal-title":"Int J Cancer"},{"issue":"3","key":"822_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/ICU.0000000000000046","volume":"25","author":"ME Aronow","year":"2014","unstructured":"Aronow ME, Chew EY. AREDS2: perspectives, recommendations, and unanswered questions. Curr Opin Ophthalmol. 2014;25(3):186\u201390. https:\/\/doi.org\/10.1097\/ICU.0000000000000046.","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"822_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/jop.2015.0083","volume":"32","author":"C Ram\u00edrez","year":"2016","unstructured":"Ram\u00edrez C, C\u00e1ceres-del-Carpio J, Chu J, et al. Brimonidine can prevent in vitro hydroquinone damage on retinal pigment epithelium cells and retinal M\u00fcller cells. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2016;32(2):102\u20138. https:\/\/doi.org\/10.1089\/jop.2015.0083.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"issue":"4","key":"822_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","volume":"127","author":"M Saylor","year":"2009","unstructured":"Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol Chic Ill 1960. 2009;127(4):402\u20136. https:\/\/doi.org\/10.1001\/archophthalmol.2009.9.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"8","key":"822_CR17","first-page":"1960","volume":"58","author":"C Ghosn","year":"2017","unstructured":"Ghosn C, Almazan A, Decker S, Burke JA. Brimonidine drug delivery system (Brimo DDS Generation 1) slows the growth of retinal pigment epithelial hypofluorescence following regional blue light irradiation in a nonhuman primate (NHP) model of geographic atrophy (GA). Investig Ophthalmol Vis Sci. 2017;58(8):1960\u20131960.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"822_CR18","first-page":"971","volume":"60","author":"WR Freeman","year":"2019","unstructured":"Freeman WR, Bandello F, Souied EH, et al. Phase 2b study of brimonidine DDS: potential novel treatment for geographic atrophy. Investig Ophthalmol Vis Sci. 2019;60(9):971\u2013971.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"822_CR19","unstructured":"Retinal Physician-Brimonidine Drug Delivery System for Geographic Atrophy. Retinal Physician. https:\/\/www.retinalphysician.com\/issues\/2019\/november-2019\/brimonidine-drug-delivery-system-for-geographic-at. Accessed 3 Dec 2019."},{"issue":"1","key":"822_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/cne.10701","volume":"461","author":"S Fuhrmann","year":"2003","unstructured":"Fuhrmann S, Grabosch K, Kirsch M, Hofmann H-D. Distribution of CNTF receptor alpha protein in the central nervous system of the chick embryo. J Comp Neurol. 2003;461(1):111\u201322. https:\/\/doi.org\/10.1002\/cne.10701.","journal-title":"J Comp Neurol"},{"issue":"12","key":"822_CR21","doi-asserted-by":"publisher","first-page":"7484","DOI":"10.1167\/iovs.12-9970","volume":"53","author":"K Kauper","year":"2012","unstructured":"Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Investig Ophthalmol Vis Sci. 2012;53(12):7484\u201391. https:\/\/doi.org\/10.1167\/iovs.12-9970.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"2","key":"822_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1172\/JCI25843","volume":"116","author":"V Luibl","year":"2006","unstructured":"Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Investig. 2006;116(2):378\u201385. https:\/\/doi.org\/10.1172\/JCI25843.","journal-title":"J Clin Investig"},{"issue":"18","key":"822_CR23","doi-asserted-by":"publisher","first-page":"11830","DOI":"10.1073\/pnas.192203399","volume":"99","author":"LV Johnson","year":"2002","unstructured":"Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer\u2019s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99(18):11830\u20135. https:\/\/doi.org\/10.1073\/pnas.192203399.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"822_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/02713680802484637","volume":"33","author":"G Landa","year":"2008","unstructured":"Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A. Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res. 2008;33(11):1011\u20133. https:\/\/doi.org\/10.1080\/02713680802484637.","journal-title":"Curr Eye Res"},{"key":"822_CR25","unstructured":"Kaplan Medical Center. Subcutaneous Copaxone as Treatment for Dry Age Related Macular Degeneration. clinicaltrials.gov; 2007. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00466076. Accessed 5 Nov 2020."},{"issue":"10","key":"822_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.oret.2018.03.001","volume":"2","author":"PJ Rosenfeld","year":"2018","unstructured":"Rosenfeld PJ, Berger B, Reichel E, et al. A randomized phase 2 study of an anti-amyloid \u03b2 monoclonal antibody in geographic atrophy secondary to age-related macular degeneration. Ophthalmol Retina. 2018;2(10):1028\u201340. https:\/\/doi.org\/10.1016\/j.oret.2018.03.001.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"822_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.visres.2007.07.025","volume":"48","author":"J-D Ding","year":"2008","unstructured":"Ding J-D, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes RC. Targeting age-related macular degeneration with Alzheimer\u2019s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res. 2008;48(3):339\u201345. https:\/\/doi.org\/10.1016\/j.visres.2007.07.025.","journal-title":"Vis Res"},{"key":"822_CR28","unstructured":"Pfizer. A phase 2 multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of Rn6g (Pf-04382923). In: subjects with geographic atrophy secondary to age-related macular degeneration. clinicaltrials.gov; 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01577381. Accessed 4 Nov 2020"},{"key":"822_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neuropharm.2014.12.038","volume":"92","author":"CG Parsons","year":"2015","unstructured":"Parsons CG, Ruitenberg M, Freitag CE, Sroka-Saidi K, Russ H, Rammes G. MRZ-99030\u2014a novel modulator of A\u03b2 aggregation: I\u2014mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer\u2019s disease, glaucoma and age-related macular degeneration (AMD). Neuropharmacology. 2015;92:158\u201369. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.12.038.","journal-title":"Neuropharmacology"},{"key":"822_CR30","unstructured":"Clinical Trials. Galimedix Therapeutics, Inc. https:\/\/www.galimedix.com\/clinical-trials. Accessed 7 Nov 2020."},{"issue":"7","key":"822_CR31","doi-asserted-by":"publisher","first-page":"e1348","DOI":"10.1038\/cddis.2014.314","volume":"5","author":"DM Mihai","year":"2014","unstructured":"Mihai DM, Washington I. Vitamin A dimers trigger the protracted death of retinal pigment epithelium cells. Cell Death Dis. 2014;5(7):e1348. https:\/\/doi.org\/10.1038\/cddis.2014.314.","journal-title":"Cell Death Dis"},{"issue":"13","key":"822_CR32","first-page":"5015","volume":"55","author":"PC Issa","year":"2014","unstructured":"Issa PC, Barnard AR, Washington I, MacLaren RE. C20-D3-Vitamin A (ALK-001) rescues the phenotype of an Abca4\u2212\/\u2212 mouse model of Stargardt disease. Investig Ophthalmol Vis Sci. 2014;55(13):5015.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"822_CR33","unstructured":"Alkeus Pharmaceuticals, Inc. A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-Week Daily Dosing of ALK-001 in Healthy Volunteers. clinicaltrials.gov; 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02230228. Accessed 21 June 2020."},{"key":"822_CR34","unstructured":"Alkeus Pharmaceuticals, Inc. A Phase 2\/3 Multicenter, randomized, double-masked, parallel-group, placebo-controlled study to investigate the safety, pharmacokinetics, tolerability, and efficacy of ALK-001 in geographic atrophy secondary to age-related macular degeneration. clinicaltrials.gov; 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03845582. Accessed 21 June 2020."},{"issue":"5","key":"822_CR35","doi-asserted-by":"publisher","first-page":"e0124940","DOI":"10.1371\/journal.pone.0124940","volume":"10","author":"C Bavik","year":"2015","unstructured":"Bavik C, Henry SH, Zhang Y, et al. Visual cycle modulation as an approach toward preservation of retinal integrity. PLoS One. 2015;10(5):e0124940. https:\/\/doi.org\/10.1371\/journal.pone.0124940.","journal-title":"PLoS One"},{"issue":"10","key":"822_CR36","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.ophtha.2018.03.059","volume":"125","author":"PJ Rosenfeld","year":"2018","unstructured":"Rosenfeld PJ, Dugel PU, Holz FG, et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2018;125(10):1556\u201367. https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.059.","journal-title":"Ophthalmology"},{"key":"822_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-319-75402-4_2","volume":"1074","author":"EE Brown","year":"2018","unstructured":"Brown EE, Lewin AS, Ash JD. Mitochondria: potential targets for protection in age-related macular degeneration. Adv Exp Med Biol. 2018;1074:11\u20137. https:\/\/doi.org\/10.1007\/978-3-319-75402-4_2.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"822_CR38","first-page":"2126","volume":"57","author":"SW Cousins","year":"2016","unstructured":"Cousins SW, Saloupis P, Brahmajoti MV, Mettu PS. Mitochondrial dysfunction in experimental mouse models of SubRPE deposit formation and reversal by the Mito-reparative drug MTP-131. Investig Ophthalmol Vis Sci. 2016;57(12):2126\u20132126.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"822_CR39","unstructured":"Retinal Physician-The ReCLAIM Phase 1 Clinical Trial of Elamipretide for Dry AMD. Retinal Physician. https:\/\/www.retinalphysician.com\/issues\/2019\/november-2019\/the-reclaim-phase-1-clinical-trial-of-elamipretide. Accessed 23 June 2020."},{"key":"822_CR40","unstructured":"Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions. BioSpace. https:\/\/www.biospace.com\/article\/stealth-biotherapeutics-announces-positive-results-for-elamipretide-in-ophthalmic-conditions\/. Accessed 22 Nov 2019."},{"key":"822_CR41","unstructured":"Kuppermann B. Risuteganib for Intermediate Dry AMD. Retina Physician. 16(November\/December 2019):28, 30, 31."},{"key":"822_CR42","unstructured":"Quiroz-Mercado H. Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate\u00ae) in Diabetic Macular Edema. In: Presented at the: The Association for Research in Vision and Ophthalmology; April 2018; Honolulu, Hawaii."},{"issue":"9","key":"822_CR43","first-page":"1944","volume":"60","author":"P Yang","year":"2019","unstructured":"Yang P, Neal SE, Jaffe GJ. Luminate protects against hydroquinone-induced injury in human RPE cells. Investig Ophthalmol Vis Sci. 2019;60(9):1944\u20131944.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"822_CR44","unstructured":"Kenney CM, Chwa M, C\u00e1ceres-del-Carpio J, et al. Effects of anti-VEGF and ALG-1001 on human retinal cells in vitro. In: Presented at the: Association for Research and Vision in Ophthalmology Annual Meeting; April 29, 2018; Honolulu, Hawaii."},{"key":"822_CR45","unstructured":"Kaiser P. Safety and efficacy of risuteganib in intermediate non-exudative age-related macular degeneration\u2014first time results from a phase 2 study. In: Presented at the: American Society of Retina Specialists Annual Meeting; July 27, 2019; Chicag, Illinois."},{"key":"822_CR46","unstructured":"Ophthalmics A, LLC. Bausch Health to Acquire Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics. Allegro ophthalmics-from theory to therapy. Published September 21, 2020. https:\/\/www.allegroeye.com\/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics\/. Accessed 5 Nov 2020."},{"issue":"1","key":"822_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2009.08.003","volume":"29","author":"JC Booij","year":"2010","unstructured":"Booij JC, Baas DC, Beisekeeva J, Gorgels TGMF, Bergen AAB. The dynamic nature of Bruch\u2019s membrane. Prog Retin Eye Res. 2010;29(1):1\u201318. https:\/\/doi.org\/10.1016\/j.preteyeres.2009.08.003.","journal-title":"Prog Retin Eye Res"},{"key":"822_CR48","unstructured":"Effects of hydralazine on ocular blood flow and laser-induced choroidal neovascularization. http:\/\/www.ijo.cn\/gjyken\/ch\/reader\/view_abstract.aspx?file_no=200904011. Accessed 11 June 2020."},{"issue":"13","key":"822_CR49","first-page":"913","volume":"51","author":"JPG Ralston","year":"2010","unstructured":"Ralston JPG, Sloan D, Waters-Honcu D, Saigal S, Torkildsen G. A pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration. Investig Ophthalmol Vis Sci. 2010;51(13):913\u2013913.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"822_CR50","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1006\/exer.2001.1094","volume":"73","author":"LV Johnson","year":"2001","unstructured":"Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res. 2001;73(6):887\u201396. https:\/\/doi.org\/10.1006\/exer.2001.1094.","journal-title":"Exp Eye Res"},{"issue":"6","key":"822_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/s1350-9462(01)00010-6","volume":"20","author":"GS Hageman","year":"2001","unstructured":"Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch\u2019s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20(6):705\u201332. https:\/\/doi.org\/10.1016\/s1350-9462(01)00010-6.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"822_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1006\/exer.1999.0798","volume":"70","author":"LV Johnson","year":"2000","unstructured":"Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in Drusen formation. Exp Eye Res. 2000;70(4):441\u20139. https:\/\/doi.org\/10.1006\/exer.1999.0798.","journal-title":"Exp Eye Res"},{"issue":"Pt 3","key":"822_CR53","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/eye.2001.142","volume":"15","author":"RF Mullins","year":"2001","unstructured":"Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of Drusen associated with glomerulonephritis: implications for the role of complement activation in Drusen biogenesis. Eye Lond Engl. 2001;15(Pt 3):390\u20135. https:\/\/doi.org\/10.1038\/eye.2001.142.","journal-title":"Eye Lond Engl"},{"issue":"20","key":"822_CR54","doi-asserted-by":"publisher","first-page":"7227","DOI":"10.1073\/pnas.0501536102","volume":"102","author":"GS Hageman","year":"2005","unstructured":"Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102(20):7227\u201332. https:\/\/doi.org\/10.1073\/pnas.0501536102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5720","key":"822_CR55","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1126\/science.1110359","volume":"308","author":"JL Haines","year":"2005","unstructured":"Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419\u201321. https:\/\/doi.org\/10.1126\/science.1110359.","journal-title":"Science"},{"issue":"5720","key":"822_CR56","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/science.1109557","volume":"308","author":"RJ Klein","year":"2005","unstructured":"Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385\u20139. https:\/\/doi.org\/10.1126\/science.1109557.","journal-title":"Science"},{"issue":"9","key":"822_CR57","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng1873","volume":"38","author":"J Maller","year":"2006","unstructured":"Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet. 2006;38(9):1055\u20139. https:\/\/doi.org\/10.1038\/ng1873.","journal-title":"Nat Genet"},{"issue":"4","key":"822_CR58","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng1750","volume":"38","author":"B Gold","year":"2006","unstructured":"Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458\u201362. https:\/\/doi.org\/10.1038\/ng1750.","journal-title":"Nat Genet"},{"issue":"6","key":"822_CR59","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJMoa072618","volume":"357","author":"JRW Yates","year":"2007","unstructured":"Yates JRW, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553\u201361. https:\/\/doi.org\/10.1056\/NEJMoa072618.","journal-title":"N Engl J Med"},{"issue":"1","key":"822_CR60","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000219686","volume":"42","author":"A Machali\u0144ska","year":"2009","unstructured":"Machali\u0144ska A, Dziedziejko V, Mozolewska-Piotrowska K, Karczewicz D, Wiszniewska B, Machali\u0144ski B. Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res. 2009;42(1):54\u20139. https:\/\/doi.org\/10.1159\/000219686.","journal-title":"Ophthalmic Res"},{"issue":"7","key":"822_CR61","doi-asserted-by":"publisher","first-page":"e2593","DOI":"10.1371\/journal.pone.0002593","volume":"3","author":"HPN Scholl","year":"2008","unstructured":"Scholl HPN, CharbelIssa P, Walier M, et al. Systemic complement activation in age-related macular degeneration. PLoS One. 2008;3(7):e2593. https:\/\/doi.org\/10.1371\/journal.pone.0002593.","journal-title":"PLoS One"},{"key":"822_CR62","unstructured":"Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration. BioSpace. https:\/\/www.biospace.com\/article\/gemini-therapeutics-enrolls-first-patient-in-phase-2a-study-of-gem103-for-dry-age-related-macular-degeneration\/. Accessed 5 Nov 2020."},{"key":"822_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf1443","author":"BL Yaspan","year":"2017","unstructured":"Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aaf1443.","journal-title":"Sci Transl Med"},{"issue":"6","key":"822_CR64","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","volume":"136","author":"FG Holz","year":"2018","unstructured":"Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666\u201377. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1544.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"822_CR65","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","volume":"121","author":"Z Yehoshua","year":"2014","unstructured":"Yehoshua Z, de Garcia Filho CAA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121(3):693\u2013701. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.044.","journal-title":"Ophthalmology"},{"key":"822_CR66","unstructured":"October 28, 2019. Zimura phase 2b trial results positive in geographic atrophy secondary to dry AMD. https:\/\/www.healio.com\/ophthalmology\/retina-vitreous\/news\/online\/06c578df-d806-4481-9f6d-85f956fe0e67\/zimura-phase-2b-trial-results-positive-in-geographic-atrophy-secondary-to-dry-amd. Accessed 3 Dec 2019."},{"key":"822_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.07.011","author":"DS Liao","year":"2019","unstructured":"Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2019. https:\/\/doi.org\/10.1016\/j.ophtha.2019.07.011 (Published online July 16).","journal-title":"Ophthalmology"},{"key":"822_CR68","unstructured":"Hemera Biosciences. A phase 1, open-label, multi-center, dose-escalating, safety and tolerability study of a single intravitreal injection of AAVCAGsCD59 in patients with advanced non-exudative (Dry) age-related macular degeneration with geographic atrophy. clinicaltrials.gov; 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03144999. Accessed 15 June 2020."},{"key":"822_CR69","unstructured":"Dugel P. CLINICAL TRIAL DOWNLOAD: data on a gene therapy for dry and wet AMD. Retina Physician. 17(April 2020):16, 17."},{"issue":"9817","key":"822_CR70","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0140-6736(12)60028-2","volume":"379","author":"SD Schwartz","year":"2012","unstructured":"Schwartz SD, Hubschman J-P, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet Lond Engl. 2012;379(9817):713\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(12)60028-2.","journal-title":"Lancet Lond Engl"},{"issue":"9967","key":"822_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet Lond Engl. 2015;385(9967):509\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(14)61376-3.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"822_CR72","doi-asserted-by":"publisher","first-page":"ORSFc1-9","DOI":"10.1167\/iovs.15-18681","volume":"57","author":"SD Schwartz","year":"2016","unstructured":"Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium for the treatment of macular degeneration: an assessment at 4 years. Investig Ophthalmol Vis Sci. 2016;57(5):ORSFc1-9. https:\/\/doi.org\/10.1167\/iovs.15-18681.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"822_CR73","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.stemcr.2015.04.005","volume":"4","author":"WK Song","year":"2015","unstructured":"Song WK, Park K-M, Kim H-J, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Rep. 2015;4(5):860\u201372. https:\/\/doi.org\/10.1016\/j.stemcr.2015.04.005.","journal-title":"Stem Cell Rep"},{"key":"822_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4097","author":"AH Kashani","year":"2018","unstructured":"Kashani AH, Lebkowski JS, Rahhal FM, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aao4097.","journal-title":"Sci Transl Med"},{"issue":"7","key":"822_CR75","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1167\/iovs.12-11239","volume":"54","author":"B Diniz","year":"2013","unstructured":"Diniz B, Thomas P, Thomas B, et al. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. Investig Ophthalmol Vis Sci. 2013;54(7):5087\u201396. https:\/\/doi.org\/10.1167\/iovs.12-11239.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"822_CR76","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.4114","volume":"36","author":"L da Cruz","year":"2018","unstructured":"da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018;36(4):328\u201337. https:\/\/doi.org\/10.1038\/nbt.4114.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"822_CR77","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","volume":"376","author":"M Mandai","year":"2017","unstructured":"Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376(11):1038\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1608368.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"822_CR78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.neo.7900071","volume":"2","author":"JG Fujimoto","year":"2000","unstructured":"Fujimoto JG, Pitris C, Boppart SA, Brezinski ME. Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. Neoplasia NYN. 2000;2(1\u20132):9\u201325.","journal-title":"Neoplasia NYN"},{"issue":"3","key":"822_CR79","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.oret.2019.09.017","volume":"4","author":"AH Kashani","year":"2020","unstructured":"Kashani AH, Uang J, Mert M, et al. Surgical method for implantation of a biosynthetic retinal pigment epithelium monolayer for geographic atrophy: experience from a phase 1\/2a study. Ophthalmol Retina. 2020;4(3):264\u201373. https:\/\/doi.org\/10.1016\/j.oret.2019.09.017.","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"822_CR80","first-page":"865","volume":"61","author":"CD Riemann","year":"2020","unstructured":"Riemann CD, Banin E, Barak A, et al. Phase I\/IIa clinical trial of human embryonic stem cell (hESC)-derived retinal pigmented epithelium (RPE, OpRegen) transplantation in advanced dry form age-related macular degeneration (AMD): interim results. Investig Ophthalmol Vis Sci. 2020;61(7):865\u2013865.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"822_CR81","first-page":"580","volume":"75","author":"JD Gass","year":"1971","unstructured":"Gass JD. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol Am Acad Ophthalmol Otolaryngol. 1971;75(3):580\u2013608.","journal-title":"Trans Am Acad Ophthalmol Otolaryngol Am Acad Ophthalmol Otolaryngol"},{"issue":"11","key":"822_CR82","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.ophtha.2006.08.015","volume":"113","author":"Complications of Age-Related Macular Degeneration Prevention Trial Research Group","year":"2006","unstructured":"Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large Drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology. 2006;113(11):1974\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2006.08.015.","journal-title":"Ophthalmology"},{"issue":"1","key":"822_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00417-017-3848-x","volume":"256","author":"G Querques","year":"2018","unstructured":"Querques G, Cicinelli MV, Rabiolo A, et al. Laser photocoagulation as treatment of non-exudative age-related macular degeneration: state-of-the-art and future perspectives. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):1\u20139. https:\/\/doi.org\/10.1007\/s00417-017-3848-x.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"822_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006537.pub3","author":"G Virgili","year":"2015","unstructured":"Virgili G, Michelessi M, Parodi MB, Bacherini D, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD006537.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"822_CR85","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1096\/fj.14-262444","volume":"29","author":"AI Jobling","year":"2015","unstructured":"Jobling AI, Guymer RH, Vessey KA, et al. Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage. FASEB J Off Publ Fed Am SocExp Biol. 2015;29(2):696\u2013710. https:\/\/doi.org\/10.1096\/fj.14-262444.","journal-title":"FASEB J Off Publ Fed Am SocExp Biol"},{"issue":"6","key":"822_CR86","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ophtha.2018.09.015","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Wu Z, Hodgson LAB, et al. Subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial. Ophthalmology. 2019;126(6):829\u201338. https:\/\/doi.org\/10.1016\/j.ophtha.2018.09.015.","journal-title":"Ophthalmology"},{"issue":"4","key":"822_CR87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/(sici)1096-9101(1998)22:4<212::aid-lsm5>3.0.co;2-s","volume":"22","author":"N Grossman","year":"1998","unstructured":"Grossman N, Schneid N, Reuveni H, Halevy S, Lubart R. 780 nm low power diode laser irradiation stimulates proliferation of keratinocyte cultures: involvement of reactive oxygen species. Lasers Surg Med. 1998;22(4):212\u20138. https:\/\/doi.org\/10.1002\/(sici)1096-9101(1998)22:4%3c212::aid-lsm5%3e3.0.co;2-s.","journal-title":"Lasers Surg Med"},{"issue":"1","key":"822_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1011-1344(98)00219-X","volume":"49","author":"T Karu","year":"1999","unstructured":"Karu T. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. J Photochem Photobiol B. 1999;49(1):1\u201317. https:\/\/doi.org\/10.1016\/S1011-1344(98)00219-X.","journal-title":"J Photochem Photobiol B"},{"issue":"3","key":"822_CR89","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/1011-1344(94)07078-3","volume":"27","author":"T Karu","year":"1995","unstructured":"Karu T, Pyatibrat L, Kalendo G. Irradiation with He\u2013Ne laser increases ATP level in cells cultivated in vitro. J Photochem Photobiol B. 1995;27(3):219\u201323. https:\/\/doi.org\/10.1016\/1011-1344(94)07078-3.","journal-title":"J Photochem Photobiol B"},{"issue":"6","key":"822_CR90","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1074\/jbc.M409650200","volume":"280","author":"MTT Wong-Riley","year":"2005","unstructured":"Wong-Riley MTT, Liang HL, Eells JT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem. 2005;280(6):4761\u201371. https:\/\/doi.org\/10.1074\/jbc.M409650200.","journal-title":"J Biol Chem"},{"issue":"5\u20136","key":"822_CR91","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.mito.2004.07.033","volume":"4","author":"JT Eells","year":"2004","unstructured":"Eells JT, Wong-Riley MTT, VerHoeve J, et al. Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. Mitochondrion. 2004;4(5\u20136):559\u201367. https:\/\/doi.org\/10.1016\/j.mito.2004.07.033.","journal-title":"Mitochondrion"},{"issue":"6","key":"822_CR92","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1073\/pnas.0534746100","volume":"100","author":"JT Eells","year":"2003","unstructured":"Eells JT, Henry MM, Summerfelt P, et al. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci USA. 2003;100(6):3439\u201344. https:\/\/doi.org\/10.1073\/pnas.0534746100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"822_CR93","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.exer.2014.02.023","volume":"122","author":"D Gkotsi","year":"2014","unstructured":"Gkotsi D, Begum R, Salt T, et al. Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Exp Eye Res. 2014;122:50\u20133. https:\/\/doi.org\/10.1016\/j.exer.2014.02.023.","journal-title":"Exp Eye Res"},{"issue":"6","key":"822_CR94","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1167\/iovs.10-6664","volume":"52","author":"R Albarracin","year":"2011","unstructured":"Albarracin R, Eells J, Valter K. Photobiomodulation protects the retina from light-induced photoreceptor degeneration. Investig Ophthalmol Vis Sci. 2011;52(6):3582\u201392. https:\/\/doi.org\/10.1167\/iovs.10-6664.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"822_CR95","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1167\/iovs.12-11018","volume":"54","author":"J Tang","year":"2013","unstructured":"Tang J, Du Y, Lee CA, Talahalli R, Eells JT, Kern TS. Low-intensity far-red light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in vitro. Investig Ophthalmol Vis Sci. 2013;54(5):3681\u201390. https:\/\/doi.org\/10.1167\/iovs.12-11018.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"822_CR96","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002632","author":"SN Markowitz","year":"2019","unstructured":"Markowitz SN, Devenyi RG, Munk MR, et al. A double-masked, randomized, sham-controlled, single-center study with photobiomodulation for the treatment of dry age-related macular degeneration. Retina Phila Pa. 2019. https:\/\/doi.org\/10.1097\/IAE.0000000000002632 (Published online August 9).","journal-title":"Retina Phila Pa"},{"issue":"4","key":"822_CR97","doi-asserted-by":"publisher","first-page":"AMD48","DOI":"10.1167\/iovs.18-24158","volume":"59","author":"ST Garrity","year":"2018","unstructured":"Garrity ST, Sarraf D, Freund KB, Sadda SR. Multimodal imaging of nonneovascular age-related macular degeneration. Investig Ophthalmol Vis Sci 2018;59(4):AMD48\u2013AMD64","journal-title":"Investig Ophthalmol Vis Sci"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-020-00822-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-020-00822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T16:09:28Z","timestamp":1611677368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-020-00822-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1007\/s40266-020-00822-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"assertion":[{"value":"13 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JK: the author declares no competing interest. EML: consultant\u2014Apellis, Roche, Novartis, Allegro, Galimedix, IMI-2 Consortium, Retrotope, and Gemini Therapeutics; research support\u2014Roche, Apellis, Novartis, Neurotech, Astellas, Allegro, and LumiThera.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}